Cleveland, Ohio 44106

  • Head and Neck Cancer


RATIONALE: SU5416 may stop the growth of head and neck cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SU5416 with chemotherapy may kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of SU5416 and paclitaxel in treating patients who have recurrent, locally advanced, or metastatic cancer of the head and neck.

Study summary:

OBJECTIVES: - Determine the maximum tolerated dose and safety of SU5416 and paclitaxel in patients with recurrent or metastatic head and neck cancer. - Determine the antiangiogenesis effect of this combination regimen in these patients. - Determine the toxicity, pharmacodynamic effects, and pharmacokinetic parameters of this combination. OUTLINE: This is a dose escalation study. Patients receive paclitaxel IV over one hour on day 1 and SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of paclitaxel and SU5416 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose limiting toxicities. PROJECTED ACCRUAL: A total of 34 patients will be accrued for this study within 9-15 months.


DISEASE CHARACTERISTICS: - Metastatic or loco-regionally recurrent malignancy of the head and neck (including salivary gland and thyroid) that is incurable by surgery or radiotherapy - At least two distinct tumor masses OR - One tumor mass at least 3 cm in diameter - No brain metastases - No pulmonary metastases as only site of disease PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - At least 12 weeks Hematopoietic: - WBC at least 3,500/mm3 - Granulocyte count at least 1,500/mm3 - Platelet count at least 100,000/mm3 - Hemoglobin greater than 9.0 g/dL Hepatic: - PT and PTT normal OR - INR ratio less than 1.1 - Bilirubin less than 1.5 mg/dL - AST and ALT less than 2 times upper limit of normal Renal: - Creatinine less than 1.5 mg/dL - Creatinine clearance greater than 60 mL/min Cardiovascular: - No New York Heart Association class III or IV heart disease - No uncompensated coronary artery disease - No history of myocardial infarction or severe or unstable angina within the past 6 months - No severe peripheral vascular disease - No deep venous thrombosis or arterial thrombosis within the past 6 months - No known hypercoagulable syndrome with predisposition to venous or arterial clots Pulmonary: - No pulmonary embolism within the past 6 months Other: - No prior cerebral hemorrhage - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - At least 3 weeks since palliative chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered - At least 4 weeks since combined chemoradiotherapy and recovered - Must be recovered from prior taxanes Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior large field radiotherapy and recovered Surgery: - Not specified



Primary Contact:

Study Chair
Scot C. Remick, MD
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center

Backup Contact:


Location Contact:

Cleveland, Ohio 44106
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.